
Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Capricor Therapeutics (CAPR) Analyst Ratings
Bulls say
Capricor Therapeutics Inc. is experiencing a substantial increase in its assessed value for deramiocel, now estimated at $2.30 billion, reflecting a significant growth from the previous valuation of $794 million. Positive Phase III clinical data for deramiocel indicates improvements in patient outcomes, such as a 1.0 point enhancement in the PUL 2.0 Mid-level Dimension and notable advancements in cardiac health metrics. With anticipated revenue growth through strategic partnerships, including the NSPharma collaboration, Capricor Therapeutics demonstrates promising potential for future net sales, further enhancing the company's financial outlook.
Bears say
Capricor Therapeutics faces significant challenges related to the clinical viability of its product deramiocel, which may encounter substantial hurdles regarding safety, efficacy, and regulatory approval. The company's financial outlook may be further hampered by a slower-than-anticipated market penetration rate, which could require additional financing under unfavorable terms, potentially leading to equity dilution. Additionally, the declining left ventricular ejection fraction (LVEF) in Duchenne muscular dystrophy patients highlights the urgency of intervention, yet the therapeutic market potential may ultimately fall short of initial projections, contributing to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares